Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 664Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others


Early access programs: Benefits, challenges, and key considerations for successful implementation

Patil Sanjaykumar

Year : 2016| Volume: 7| Issue : 1 | Page no: 4-8

   This article has been cited by
1 Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands
Marianne Luyendijk, Hedwig Blommestein, Carin Uyl-de Groot, Sabine Siesling, Agnes Jager
JAMA Network Open. 2023; 6(2): e2256170
[Pubmed]  [Google Scholar] [DOI]
2 PACIFIC in the Real World
Caroline O’Leary, Jarushka Naidoo
Journal of Thoracic Oncology. 2023; 18(2): 133
[Pubmed]  [Google Scholar] [DOI]
3 Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
D. Bello Roufai, A. Gonçalves, T. De La Motte Rouge, S. Akla, C. Blonz, J. Grenier, J. Gligorov, M. Saghatchian, C. Bailleux, H. Simon, I. Desmoulins, Z. Tharin, E. Renaud, M. Bertho, M-A Benderra, S. Delaloge, L. Robert, P. Cottu, J. Y. Pierga, D. Loirat, A. Bertucci, B. Renouf, F. C. Bidard, F. Lerebours
Oncogene. 2023;
[Pubmed]  [Google Scholar] [DOI]
4 Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV -1 in need of parenteral antiretroviral therapy
Ronald D'Amico, Santiago Cenoz Gomis, Riya Moodley, Rodica Van Solingen-Ristea, Bryan Baugh, Erika Van Landuyt, Veerle Van Eygen, Sherene Min, Amy Cutrell, Caroline Foster, Daniella Chilton, Sabine D. Allard, Annemiek Ruiter
HIV Medicine. 2022;
[Pubmed]  [Google Scholar] [DOI]
5 Early Access to Medicines: Use of Multicriteria Decision Analysis (MCDA) as a Decision Tool in Catalonia (Spain)
Montse Gasol, Noelia Paco, Laura Guarga, Josep Ŕngel Bosch, Caridad Pontes, Mercč Obach
Journal of Clinical Medicine. 2022; 11(5): 1353
[Pubmed]  [Google Scholar] [DOI]
6 International Country-Level Trends, Factors, and Disparities in Compassionate Use Access to Unlicensed Products for Patients With Serious Medical Conditions
Paul Aliu, Séverine Sarp, Ramona Reichenbach, Sigrid Behr, Paige Fitzsimmons, Mansurahmad Shamlajee, Surya Prakash Kola, Samantha Nunes Radimerski, Emil Scosyrev
JAMA Health Forum. 2022; 3(4): e220475
[Pubmed]  [Google Scholar] [DOI]
7 Educational needs, perception, and perspectives of oncologists regarding compassionate use programs in Asia
Manmohan Singh,Ankita Jain,Wade Fang,Peter Ong,Roberto Uehara,Jingming Zhong
Current Medical Research and Opinion. 2021; : 1
[Pubmed]  [Google Scholar] [DOI]
8 Access to unlicensed medicines, who should pay when they are not provided for free?
Kieron David Lewis
Medicine Access @ Point of Care. 2021; 5: 2399202621
[Pubmed]  [Google Scholar] [DOI]
9 Gene therapy companies have an ethical obligation to develop expanded access policies
Lisa Kearns,Carolyn Riley Chapman,Kenneth I. Moch,Arthur L. Caplan,Tom Watson,Andrew McFadyen,Pat Furlong,Alison Bateman-House
Molecular Therapy. 2021;
[Pubmed]  [Google Scholar] [DOI]
10 Zugelassene Systemtherapien in der Dermatologie
Monika Kleinhans,Carolin Funke-Lorenz,Joachim Dissemond
Der Hautarzt. 2021;
[Pubmed]  [Google Scholar] [DOI]
11 Digital Transformation in Medical Affairs Sparked by the Pandemic: Insights and Learnings from COVID-19 Era and Beyond
Daniel Furtner, Salil Prakash Shinde, Manmohan Singh, Chew Hooi Wong, Sajita Setia
Pharmaceutical Medicine. 2021;
[Pubmed]  [Google Scholar] [DOI]
12 Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme
Camille Taillé,Pascal Chanez,Gilles Devouassoux,Alain Didier,Christophe Pison,Gilles Garcia,Jeremy Charriot,Stéphane Bouée,Alina Gruber,Celine Pribil,Arnaud Bourdin,Marc Humbert
European Respiratory Journal. 2020; 55(6): 1902345
[Pubmed]  [Google Scholar] [DOI]
13 Ethics framework for treatment use of investigational drugs
Jan Borysowski,Andrzej Górski
BMC Medical Ethics. 2020; 21(1)
[Pubmed]  [Google Scholar] [DOI]
14 Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas
Kathryn J. Hammer,Vanessa C. Copeland,Elizabeth T. Loggers,Seth M. Pollack,Michael J. Wagner,Lee D. Cranmer
American Journal of Clinical Oncology. 2020; 43(6): 446
[Pubmed]  [Google Scholar] [DOI]
15 Understanding the challenges and ethical aspects of compassionate use of drugs in emergency situations
PardeepKumar Goyal,Roli Mathur,Bikash Medhi
Indian Journal of Pharmacology. 2020; 52(3): 163
[Pubmed]  [Google Scholar] [DOI]
16 Compassionate drug use: Current status in India
YashashriC Shetty,Smita Brahma,PS Manjesh
Perspectives in Clinical Research. 2020; 11(1): 3
[Pubmed]  [Google Scholar] [DOI]
17 To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma
Peter Martin,Andre Goy,Radhakrishnan Ramchandren,Lucille Ferrante,Anil Londhe,Tracy McGowan,Nancy L Bartlett
Journal of Oncology Pharmacy Practice. 2019; 25(4): 1027
[Pubmed]  [Google Scholar] [DOI]
18 What do patients with unmet medical needs want? A qualitative study of patients’ views and experiences with expanded access to unapproved, investigational treatments in the Netherlands
Eline M. Bunnik,Nikkie Aarts
BMC Medical Ethics. 2019; 20(1)
[Pubmed]  [Google Scholar] [DOI]
19 Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology
Olga Löblová,Marcell Csanádi,Piotr Ozieranski,Zoltán Kaló,Lawrence King,Martin McKee
Health Policy. 2019;
[Pubmed]  [Google Scholar] [DOI]
20 Patterns of Alternative Access: unpacking the Slovak extraordinary drug reimbursement regime 2012-2016
Olga Löblová,Marcell Csanádi,Piotr Ozieranski,Zoltán Kaló,Lawrence King,Martin McKee
Health Policy. 2019;
[Pubmed]  [Google Scholar] [DOI]
21 Expanding Patient Access to Investigational New Drugs
Gail A. Van Norman
JACC: Basic to Translational Science. 2018; 3(3): 403
[Pubmed]  [Google Scholar] [DOI]
22 Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
Ajai Chari,Sagar Lonial,Tomer M. Mark,Amrita Y. Krishnan,Keith E. Stockerl-Goldstein,Saad Z. Usmani,Anil Londhe,Delores Etheredge,Sarah Fleming,Baolian Liu,Jon Ukropec,Thomas S. Lin,Sundar Jagannath,Ajay K. Nooka
Cancer. 2018;
[Pubmed]  [Google Scholar] [DOI]
23 Physician perspectives on compassionate use in pediatric oncology
Scott Moerdler,Lindy Zhang,Elena Gerasimov,Chong Zhu,Tamar Wolinsky,Michael Roth,Nancy Goodman,Daniel A. Weiser
Pediatric Blood & Cancer. 2018; : e27545
[Pubmed]  [Google Scholar] [DOI]
24 Identification, Prioritization, and Treatment of Mutations Identified by Next-Generation Sequencing
Aaron S. Mansfield,Ben Ho Park,Michael P. Mullane
American Society of Clinical Oncology Educational Book. 2018; (38): 873
[Pubmed]  [Google Scholar] [DOI]
25 A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice
Beatrice Borelli,Gemma Zucchelli,Daniele Rossini,Chiara Cremolini,Carlotta Antoniotti,Roberto Moretto,Federica Marmorino,Camilla Colombo,Francesca Vannini,Laura Delliponti,Mario Spione,Elena Ongaro,Gianluca Masi,Isa Maura Brunetti,Elisabetta Pfanner,Lisa Salvatore,Alfredo Falcone
Colorectal Cancer. 2018;
[Pubmed]  [Google Scholar] [DOI]
26 An overview of Compassionate Use Programs in the European Union member states
Gayathri Balasubramanian,Suman Morampudi,Pankdeep Chhabra,Arun Gowda,Behsad Zomorodi
Intractable & Rare Diseases Research. 2016; 5(4): 244
[Pubmed]  [Google Scholar] [DOI]


Read this article